// App-Quantinova.ai

: The Impact of Chemotherapy on Phenotype and Function of Non-Malignant T-Cells in Patients with T-Cell Lymphoma

Researchers

Presenter

  • Meryl Colton

Principal Investigators

  • Kimberly Jordan

  • Eduardo Davila

  • Xander Bradeen

  • Jasmine Zain

  • Pierluigi Porcu

  • Bradley M. Haverkos

Medical Centers

  • Division of Oncology, University of Colorado, Aurora, CO

  • City of Hope Comprehensive Cancer Center, Duarte, CA

  • Department of Immunology & Microbiology/Human Immunology & Immunotherapy Initiative, University of Colorado/Anschutz Medical Campus, Aurora, CO

  • Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO

  • Sidney Kimmel Cancer Center at Jefferson Health, Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • T-cell lymphoma

Biomarkers

  • Carboxypeptidase B1

  • C-C Motif Chemokine Receptor 4

  • C-C Motif Chemokine Receptor 7

  • C-X-C motif chemokine receptor 3

  • Protein Tyrosine Phosphatase, Receptor Type C

  • Cytokine

  • Cytotoxic T-lymphocyte-associated protein 4

  • Programmed cell death protein 1

  • Interleukin 17A

  • Interleukin 4

  • Interleukin-2

Drug/Treatment

  • Interferon

  • lonomycin

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved